WebSep 5, 2015 · Overall Survival versus Survival Rate: The term overall survival can be easily confused with the survival rate or can be easily thought as the survival rate. While these … WebApr 10, 2024 · With a median follow-up of 13 months, there were significant differences in overall survival (OS) and leukemia-free survival (LFS) between both groups (Fig. 1B, C).Patients who underwent allo-HSCT after CAR T-cell therapy in the DAC or the CON group had higher OS and LFS than those without allo-HSCT, although the number of patients in …
Overall Survival: Still the Gold Standard - LWW
WebJan 7, 2024 · A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma (NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic target in NSCLC. Treatment strategies for patients with advanced‑stage NSCLC have markedly changed, from the empirical use of cytotoxic agents to targeted regimens. … WebThere is an ongoing debate about the relative merits of overall survival (OS) and other metrics that can be used as primary end points in cancer clinical trials. Although survival time is arguably the most objective metric for assessing the efficacy of anticancer treatment, OS as a clinical-trial end point needs to be conceptually distinguished from … horror story hero
Overall survival and objective response in advanced unresectable ...
WebMar 8, 2024 · Background Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the … WebJul 27, 2024 · In randomized controlled trials in oncology, changes in quality of life are usually reported together with a description of the differences considered a priori to be … WebOct 14, 2024 · In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42–65, p < 0.0001) and overall survival … horror story hindi mp3